Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.47 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7308476 | 0.89 | ALDH1A1 (0.43) | HTTHPGDALDH1A1 | |
| SCHEMBL1466280 | 0.88 | ALDH1A1 (0.50) | NPSR1MAPTKMT2AALDH1A1GAA | |
| SCHEMBL29896410 | 0.88 | ALDH1A1 (0.50) | NPSR1MAPTKMT2AALDH1A1GAA | |
| SCHEMBL5773042 | 0.87 | IDO1 (0.48) | HTTMAP2K4PDE10ANPC1RAB9A | |
| SCHEMBL7308745 | 0.86 | AR (0.41) | HTTPDE10ANPC1RAB9AHPGD | |
| SCHEMBL5775365 | 0.85 | SLC6A2 (0.41) | HTTPDE10AHPGDMAPTKMT2A | |
| SCHEMBL5774340 | 0.84 | NHERF1 (0.47) | HTTMAP2K4NPSR1CA12CA9 | |
| SCHEMBL7072222 | 0.84 | MAPK1 (0.49) | HTTMAP2K4RAB9AHPGDMAPK1 | |
| SCHEMBL7306658 | 0.84 | PDPK1 (0.42) | RAB9AHPGDMAPTKMT2AALDH1A1 | |
| SCHEMBL7308514 | 0.84 | GAA (0.51) | NPSR1NPC1RAB9AMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674906-B2 | Tetracyclic immunomodulatory compounds | ACTIVE BIOTECH AB (SE) | 2010-03-09 | — | — | US | disclosed |
| US-7674906-B2 | Tetracyclic immunomodulatory compounds | ACTIVE BIOTECH AB (SE) | 2010-03-09 | — | — | US | disclosed |
| EP-1572689-B1 | TETRACYCLIC IMMUNOMODULATORY COMPOUNDS | ACTIVE BIOTECH AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| EP-1409485-B1 | IMMUNOMODULATING COMPOUNDS | ACTIVE BIOTECH AB (SE) | 2006-04-26 | — | — | EP | disclosed |
| CN-1249063-C | Novel Immunomodulatory Compounds | ACTIVE BIOTECH AB (SE) | 2006-04-05 | — | — | CN | disclosed |
| CN-1522254-A | Novel Immunomodulatory Compounds | ��Ծ���＼���ɷݹ�˾ | 2004-08-18 | — | — | CN | disclosed |
| EP-1409485-A1 | NOVEL IMMUNOMODULATING COMPOUNDS | Active Biotech AB (SE) | 2004-04-21 | — | — | EP | disclosed |
| US-6642249-B2 | 3-Oxo-pyrazolo(4,3-c) -quinolin-2-yl, -thiochroman-2-yl, or -chromen-2-yl derivatives; CD80 antagonists | ACTIVE BIOTECH AB (SE) | 2003-11-04 | — | — | US | disclosed |
| US-20030022913-A1 | Novel immunomodulating compounds | ACTIVE BIOTECH AB (SE) | 2003-01-30 | — | — | US | disclosed |
| WO-2003004495-A1 | NOVEL IMMUNOMODULATING COMPOUNDS | ACTIVE BIOTECH AB (SE) | 2003-01-16 | — | — | WO | disclosed |
| EP-0022078-A1 | Pyrazolo-quinolines, processes for their production, and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022913-A1 | Novel immunomodulating compounds | CD40, ICOS, CD40LG | HTT 3545/4885PLA2G10 1295/4885MAP2K4 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.